Institutional investors purchased a net $4.1 million shares of ANTH during the quarter ended June 2016. This may signal that the smart money is gaining interest in this company as the 60.88% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
BVF PARTNERS LP Bought 4.6 Million shares of Anthera Pharmaceuticals I...